Quick answer: Yes. Tirzepatide is a peptide: a synthetic chain of 39 amino acids built on the GIP sequence and modified with a fatty-diacid side chain, and it activates both the GIP and GLP-1 receptors. "Tirz" is community shorthand for it. An approved medicine containing tirzepatide is made by its originator, Eli Lilly. This guide is about the research compound sold for laboratory work, which is a different matter, and it makes no claims about use in people.
Is tirzepatide a peptide?
People ask this because tirzepatide is usually discussed alongside drugs, and "peptide" can sound like a separate category. It is not. A peptide is a chain of amino acids, and tirzepatide is exactly that: a linear chain of 39 residues. What sets it apart from short research peptides is that it is a chemically engineered analog, not a natural sequence. Several positions are replaced with non-natural amino acids, and a fatty-diacid chain is attached through a linker to one of the lysine side chains.
That fatty chain is the design feature that matters most. It lets the molecule bind albumin in circulation, which in animal and clinical pharmacology gives it a much longer half-life than an unmodified peptide of the same length. The same idea is used in semaglutide and in retatrutide, which is why the three are often grouped together. Our structure and synthesis article covers the sequence in detail.
What "tirz" means
"Tirz" is simply shorthand for tirzepatide, in the same way "sema" stands for semaglutide and "reta" for retatrutide. Some sellers use brand-style names for the research material, so it is worth matching any listing to the compound name, the vial size and the declared content rather than to a nickname. The size we supply is a 30 mg research vial.
Two receptors, one molecule
The pharmacological interest in tirzepatide is that it acts on two incretin receptors at once, the GIP receptor and the GLP-1 receptor. Published in vitro work describes it as an imbalanced and biased agonist: it is more potent at the GIP receptor than at the GLP-1 receptor, and at the GLP-1 receptor it shows a different signalling pattern from the native hormone, with less recruitment of beta-arrestin. Researchers use that profile as a reference point when they compare single and dual agonists in cell assays.
To see how it sits next to its relatives, our retatrutide vs tirzepatide comparison contrasts the dual and triple agonists, and the semaglutide and tirzepatide buyer's guide covers the practical side. The mechanism of action article goes through the signalling steps.
Research compound versus approved medicine
This distinction needs to be stated plainly. Tirzepatide is the active ingredient in medicines approved by regulators and made by Eli Lilly. Those products are manufactured and controlled under pharmaceutical rules, and they are outside the scope of this site. The tirzepatide that V8 Peptides supplies is sold only for laboratory research, such as in vitro assays and preclinical models. It is not the approved product, it is not a substitute for it, and nothing here is guidance for use in people or animals.
The difference also explains why documentation matters. An approved medicine comes with regulatory release testing. Research material comes with whatever testing its supplier chooses to do and publish. A buyer has to read the certificate to learn what is in the vial.
What to check on a tirzepatide listing
- A certificate for the lot. It should name the lot code, test date and laboratory, and show a measured purity figure rather than only a specification limit.
- HPLC purity with the chromatogram. Understanding HPLC purity explains the trace.
- Measured content. Purity says how much of the sample is the target peptide; content says how much peptide is in the vial. For a 30 mg vial the measured amount should be close to the label.
- Endotoxin and sterility. These matter as much as purity for cell-based work.
- A report you can verify. The best certificates can be checked with the laboratory that issued them.
If the layout is unfamiliar, how to read a COA walks through a certificate line by line. Our wider supplier checklist is in how to choose a research peptide supplier.
Purity is harder than it looks for long, modified peptides
A 39-residue peptide with non-natural amino acids and a lipid side chain is much harder to make well than a short one. Each coupling step has a small failure rate, and the failures multiply over a long chain, leaving a mixture of deletion sequences and truncated products that are chemically similar to the target. Purification has to separate them, and that costs yield. This is the main reason the gap between a well-made and a poorly made batch is wider for this compound than for a short tripeptide, and it is why a chromatogram, not just a headline number, is worth reading.
Our tirzepatide purity testing article describes the typical impurities, and where to buy tirzepatide applies the checklist to this specific compound.
What drives the price of research tirzepatide
Searches for "tirzepatide peptide price" turn up a wide spread, and the reasons are mostly technical. A long, lipidated peptide has a lower synthesis yield than a short one, purification discards impure fractions, and independent testing for each lot costs real money. Vial size changes the arithmetic as well: a 30 mg vial carries its own handling and testing costs, so its price per milligram is not simply a multiple of a smaller size. A price far below the rest of the market is a prompt to look harder at the documentation, since the saving usually comes from a shortcut in one of those steps. Our pricing article goes through the cost drivers in more detail.
How it compares with its relatives
Within the incretin family, tirzepatide sits in the middle. Semaglutide is the single-receptor reference, tirzepatide adds the GIP receptor, and retatrutide adds the glucagon receptor on top of that. For experiments, that ladder lets a researcher change one variable at a time, which is the main reason all three appear in comparative studies. Our semaglutide vs tirzepatide article sets out the first step on that ladder, and the guide to reta covers the last.
Storage and handling
The compound is supplied as a lyophilized powder. General laboratory practice is to keep the sealed vial refrigerated and protected from light, heat and moisture, and to avoid repeated temperature cycling. After reconstitution for an assay, stability falls and working solutions are best prepared fresh. Our reconstitution and storage article has the details, and the calculator guide helps with concentration arithmetic.
What V8 Peptides publishes for tirzepatide
We supply tirzepatide as a 30 mg research vial. A certificate of analysis from Accumark Labs is published for the 30 mg lot, with measured purity, content, endotoxin and PCR sterility results, and you can verify it on the laboratory's own site using the sample code printed on the report. It is on our COA page. We have not published certificates for other products that lack one, and we say so on those product pages.
Frequently asked questions
Is tirzepatide a peptide?
Yes. It is a synthetic chain of 39 amino acids, engineered with non-natural residues and a fatty-diacid side chain, and it activates both the GIP and GLP-1 receptors.
What does "tirz" mean?
It is community shorthand for tirzepatide, like "sema" for semaglutide and "reta" for retatrutide.
Is research tirzepatide the same as the approved medicine?
No. The approved medicines are made by Eli Lilly under pharmaceutical controls. Research material is sold for laboratory use only, and nothing here is guidance for use in people or animals.
What is special about its receptor profile?
It acts on two incretin receptors. Published work describes it as an imbalanced, biased agonist that is more potent at the GIP receptor than at the GLP-1 receptor.
Why is purity harder for this peptide?
It is long, modified and lipidated, so synthesis produces many closely related impurities that must be separated out. Reading the chromatogram matters.
What should a COA show?
Lot code, test date, laboratory, measured HPLC purity with the chromatogram, measured content, and endotoxin and sterility results, ideally verifiable with the lab.
Does V8 Peptides publish a COA for tirzepatide?
Yes, for the 30 mg lot, on the COA page. It can be verified on the laboratory's site.
Is this guide advice for use in people?
No. Tirzepatide from V8 Peptides is supplied for laboratory research only.
Where to go next
For a fuller picture of the compound, start with the tirzepatide research overview and the research FAQ. To check the certificates we publish and verify them yourself, visit the COA page.
References
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14.
- Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180-2193.
For laboratory research use only. Not for human or animal consumption. Not a drug, food or cosmetic. This article is educational and describes published research; it makes no claims about outcomes in people or animals.